MA3 Inhibitors
MA3 inhibitors, a group of chemical compounds, predominantly act by modulating signaling pathways that could involve MA3, thereby indirectly leading to its functional inhibition. These compounds mainly target the PI3K/AKT/mTOR and MAPK/ERK signaling pathways, which are key modulators of various cellular processes. Sunitinib, Rapamycin, LY294002, GDC-0941, and Akti-1/2 are primarily involved in the PI3K/AKT/mTOR pathway. Sunitinib, an inhibitor of receptor tyrosine kinases, can suppress the initial stages of this pathway. Rapamycin and LY294002 inhibit mTOR and PI3K, respectively, essential components of this pathway. GDC-0941, another PI3K inhibitor, and Akti-1/2, which selectively inhibits AKT1 and AKT2 isoforms, also suppress this pathway. By blocking these components, these inhibitors can disrupt downstream signaling that might involveMA3, leading to its functional decline.
In contrast, PD98059, U0126, Sorafenib, BIX02189, PD0325901, SB202190, and SB203580 target the MAPK/ERK pathway. PD98059 and U0126 are selective inhibitors of MEK1, a key component of this pathway, while Sorafenib, a multi-kinase inhibitor, can obstruct several signaling pathways, including MAPK/ERK. BIX02189 inhibits MEK5, another crucial component of this pathway, while PD0325901 selectively inhibits both MEK1 and MEK2. SB202190 and SB203580 inhibit p38 MAPK, a part of the p38/MAPK pathway. By inhibiting these key components, these compounds can disrupt the downstream signaling processes that involve the functionality of MA3, indirectly leading to its functional inhibition
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib inhibits receptor tyrosine kinases, which are upstream of many signaling pathways including PI3K/AKT/mTOR. By blocking these kinases, Sunitinib can suppress downstream signaling that could potentially involve MA3, indirectly leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific inhibitor of mTOR, a pivotal component of the PI3K/AKT/mTOR pathway. By inhibiting mTOR, Rapamycin can disturb downstream signaling processes that may involve the functionality of MA3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, a key initiator of the PI3K/AKT/mTOR pathway. The inhibition of PI3K can disrupt downstream signaling events that potentially involve the activity of MA3, leading to its functional decline. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941, a potent inhibitor of PI3K, can suppress the PI3K/AKT/mTOR signaling pathway. By blocking this pathway, GDC-0941 can indirectly inhibit the functioning of MA3, if MA3 is involved in this pathway. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
Akti-1/2 selectively inhibits AKT1 and AKT2 isoforms. By suppressing these isoforms, Akti-1/2 can disrupt the PI3K/AKT/mTOR pathway, potentially leading to the functional inhibition of MA3, if MA3 is a part of this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK1, which is involved in the MAPK/ERK pathway. This inhibition can disrupt downstream signaling events, potentially leading to the functional inhibition of MA3, if MA3 operates within this pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that can block several signaling pathways, including the MAPK/ERK pathway. By inhibiting this pathway, Sorafenib can indirectly inhibit the function of MA3, if MA3 is involved in this pathway. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $224.00 $386.00 | 5 | |
BIX02189 inhibits MEK5, a component of the MAPK/ERK pathway. This inhibition can disrupt downstream signaling events, possibly leading to the functional inhibition of MA3, if MA3 is a component of this pathway. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190 selectively inhibits p38 MAPK, a key component in the p38/MAPK pathway. By inhibiting p38 MAPK, SB202190 can disrupt downstream signaling processes, possibly leading to the functional inhibition of MA3, if MA3 operates within this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK. By blocking the p38/MAPK pathway, SB203580 can indirectly inhibit the functioning of MA3, if MA3 is involved in this pathway. | ||||||